- Home
- DC vs STTK Comparison
DC vs STTK Comparison
Compare DC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DC | STTK |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.6M | 652.4M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DC | STTK |
|---|---|---|
| Price | $5.25 | $5.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $12.26 | ★ $15.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.03 | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.79 | $1.72 |
| 52 Week High | $7.25 | $8.33 |
Technical Indicators
Market Signals| Indicator | DC | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 42.07 |
| Support Level | $4.22 | $5.19 |
| Resistance Level | $5.45 | $7.66 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 8.30 | 21.87 |
Price Performance
Historical ComparisonAbout DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company focused on revitalizing the Homestake District in Lead, South Dakota. The company holds gold mineral properties surrounding the historic Homestake Mine and is advancing key projects, including the Richmond Hill Project.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.